Young Hak Kim
Overview
Explore the profile of Young Hak Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
2754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, et al.
Sci Rep
. 2023 Feb;
13(1):2117.
PMID: 36747076
No abstract available.
12.
Nakamura R, Yamada T, Tanaka S, Sasada A, Shiotsu S, Tani N, et al.
Cancer Med
. 2023 Jan;
12(8):9097-9105.
PMID: 36707978
Background: Lung cancer patients face a high risk of thromboembolism (TE), which is considered to be a poor prognostic factor. However, the impact of symptomatic cerebral infarction (CI) and pulmonary...
13.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):12.
PMID: 36702855
Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to...
14.
Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, et al.
Cancer Immunol Immunother
. 2023 Jan;
72(6):1699-1707.
PMID: 36617602
Background: Current evidence indicates that immune checkpoint inhibitors (ICIs) have a limited efficacy in patients with lung cancer harboring epidermal growth factor receptor (EGFR) mutations. However, there is a lack...
15.
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, et al.
Sci Transl Med
. 2022 Dec;
14(675):eabq0021.
PMID: 36516270
Despite the success of cancer immunotherapies such as programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed...
16.
Xu Y, Huang Z, Fang J, Liu A, Lu H, Yu X, et al.
Transl Lung Cancer Res
. 2022 Jul;
11(6):1069-1078.
PMID: 35832454
Background: Second-line treatment options for small cell lung cancer (SCLC) are limited. Preclinical research shows that inhibition of poly (ADP-ribose) polymerase (PARP) could upregulate programmed death-ligand 1 (PD-L1), and thus...
17.
Iwamoto N, Kim Y, Iwatsubo S, Nishimura Y, Funada Y
J Thorac Dis
. 2022 Mar;
14(1):207-209.
PMID: 35242383
No abstract available.
18.
Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, et al.
Sci Rep
. 2021 Dec;
11(1):23677.
PMID: 34880386
Chronic obstructive pulmonary disease (COPD) may coexist with lung cancer, but the impact on prognosis is uncertain. Moreover, it is unclear whether pharmacological treatment for COPD improves the patient's prognosis....
19.
Yamasaki N, Kim Y, Iwatsubo S, Nishimura Y, Funada Y
Clin Lung Cancer
. 2021 Nov;
23(3):e171-e172.
PMID: 34756510
No abstract available.
20.
Okamoto M, Kim Y, Ouchi A, Yamaoka T, Iwamoto N, Iwatsubo S, et al.
Respir Med Case Rep
. 2021 Nov;
34:101529.
PMID: 34745866
A 69-year-old man visited our hospital due to an abnormal shadow on a chest X-ray. Chest CT showed a mass shadow in his left lower lobe accompanied by an infiltrative...